Precision Medicine News and Research

RSS

Weill Cornell and NewYork-Presbyterian create pioneering Institute for Precision Medicine

Recognizing that medicine is not "one size fits all," Weill Cornell Medical College and NewYork-Presbyterian Hospital have created the pioneering Institute for Precision Medicine at Weill Cornell and NewYork-Presbyterian/Weill Cornell Medical Center. This new, cutting-edge translational medicine research hub will explore the new frontier of precision medicine, offering optimal targeted, individualized treatment based on each patient's genetic profile.

1 Feb 2013

Acute schizophrenia shows increased NMDA-R antibody prevalence

Patients with acute schizophrenia have an increased prevalence of N-methyl-D-aspartate glutamate receptor antibodies that is distinct from that seen in NMDA-R encephalitis, scientists have found.

31 Jan 2013

Clarient adopts QIAGEN’s therascreen KRAS test to diagnose colorectal cancer

QIAGEN N.V. today announced that Clarient - a GE Healthcare Company and leading provider of cancer laboratory testing services in the United States - has adopted the use of the therascreen KRAS RGQ PCR Kit (therascreen KRAS test) as a companion diagnostic to guide the use of Erbitux (cetuximab) as a treatment in patients with metastatic colorectal cancer.

From QIAGEN Manchester Limited 30 Jan 2013

Phenformin decreases size of lung tumors and increases survival in mice

Ever since discovering a decade ago that a gene altered in lung cancer regulated an enzyme used in therapies against diabetes, Reuben Shaw has wondered if drugs originally designed to treat metabolic diseases could also work against cancer.

30 Jan 2013

Impulsiveness linked to severe clinical features in bipolar disorder

Researchers have confirmed that trait-impulsiveness is associated with bipolar disorder and provide additional evidence of it being linked to a more severe clinical expression of the disease.

25 Jan 2013

World Cancer Day to focus on awareness and prevention, importance of research

Cancer takes the lives of some 7.6 million people worldwide each year, according to the World Health Organization. And while the upcoming World Cancer Day will focus on a global message of cancer awareness and prevention, the importance of cancer research also will resonate.

23 Jan 2013

New apatamer can boost therapeutic effect of cell-based vaccines

A small compound called an aptamer that specifically targets and stimulates a human immune cell can greatly increase the effectiveness of an immunotherapeutic drug designed to destroy malignant or virus-infected cells. The development of a novel apatamer that recognizes activated T-lymphocytes and can boost the therapeutic effect of cell-based vaccines is described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers.

23 Jan 2013

SV Bio, Mayo Clinic partner on whole genome diagnostics and interpretation

Mayo Clinic and Silicon Valley Biosystems (SV Bio) today announced a strategic collaboration for whole genome diagnostics and interpretation at the Mayo Clinic Center for Individualized Medicine and Mayo Medical Laboratories.

23 Jan 2013

Study refocuses on how neuroblastoma tumors evolve in response to medicine and other factors

An extensive genomic study of the childhood cancer neuroblastoma reinforces the challenges in treating the most aggressive forms of this disease. Contrary to expectations, the scientists found relatively few recurrent gene mutations—mutations that would suggest new targets for neuroblastoma treatment. Instead, say the researchers, they have now refocused on how neuroblastoma tumors evolve in response to medicine and other factors.

21 Jan 2013

Astellas announces FDA acceptance of Tarceva sNDA for EGFR activating mutation-positive NSCLC

Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc., today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental New Drug Application (sNDA) for Tarceva (erlotinib) for first-line use in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) activating mutations.

17 Jan 2013

Trovagene, MD Anderson partner to detect transrenal BRAF mutations in metastatic cancers

Trovagene, Inc., a developer of transrenal molecular diagnostics, announced that it has entered into a clinical collaboration with The University of Texas MD Anderson Cancer Center to detect transrenal BRAF mutations in the urine of patients with advanced or metastatic cancers.

3 Jan 2013

18F-FDG PET/CT may become important distant staging modality in patients with breast cancer

New research published in the January issue of The Journal of Nuclear Medicine shows that 18F-fludeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) imaging offers significant prognostic stratification information at initial staging for patients with locally advanced breast cancer. When compared to conventional imaging, 18F-FDG PET/CT more accurately showed lesions in the chest, abdomen and bones in a single session, changing management for more than 50 percent of the patients in the study.

3 Jan 2013

Multiple Myeloma Research Foundation, Bristol-Myers Squibb announce partnership

The Multiple Myeloma Research Foundation (MMRF) today announced that Bristol-Myers Squibb has joined the MMRF pre-competitive consortium (PCC) to discover and accelerate new approaches to treating multiple myeloma through the organization's Personalized Medicine Initiative (PMI).

15 Dec 2012

Pfizer joins WIN Consortium to improve personalized cancer care

Worldwide Innovative Network (WIN) in personalized cancer medicine consortium today proudly announced that Pfizer, Inc (NYSE:PFE) is the first pharmaceutical company to become a member of the consortium. Founded on the recognition that greater success can be achieved through collaboration than any organization can achieve alone, the WIN Consortium is a global network of leading academic, industry, and patient advocacy organizations working to make personalized cancer care a reality for patients worldwide.

10 Dec 2012

New assay test shows positive results for patients with recurrent or metastatic breast cancer

When breast cancer advances, the patient doesn't have the luxury of time. Finding the right type of chemotherapy as quickly as possible is a critical factor for the patient's success and, until now, predicting the patient's sensitivity to chemotherapy has often been a shot in the dark.

10 Dec 2012

New survival results from Genentech’s Perjeta Phase III combination study on HER2-positive mBC

Genentech, a member of the Roche Group, today announced updated survival results from the Phase III CLEOPATRA study, which showed that the combination of Perjeta (pertuzumab), Herceptin (trastuzumab) and docetaxel chemotherapy significantly extended the lives (overall survival) of people with previously untreated HER2-positive metastatic breast cancer (mBC), compared to Herceptin, chemotherapy and placebo.

10 Dec 2012

Genomic tests increase accuracy of breast cancer diagnosis

The latest generation of genomic tests for breast cancer can improve physicians' ability to diagnose the disease and more precisely tailor each patient's treatment, according to a study being presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). The study examined the first commercially available genomic tests to determine the molecular subtype of a breast cancer tumor.

7 Dec 2012

Engineers develop simple and inexpensive way to create 3-D brain tissues in lab dishes

Borrowing from microfabrication techniques used in the semiconductor industry, MIT and Harvard Medical School (HMS) engineers have developed a simple and inexpensive way to create three-dimensional brain tissues in a lab dish.

30 Nov 2012

Study identifies gene signature associated with resistance to cancer therapies

Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced the publication in the November 21st issue of the prestigious scientific journal "Cell" of a study that identifies a gene signature that is associated with resistance to a broad range of cancer therapies in multiple cancer types.

28 Nov 2012

Renowned biotech researcher to receive TJU's Lennox K. Black International Prize

Thomas Jefferson University will honor the renowned biotech researcher whose discoveries led to a slew of innovative drugs that revolutionized treatment including Herceptin-one of the first gene-based medications for breast cancer-with its prestigious Lennox K. Black International Prize for Excellence in Biomedical Research.

27 Nov 2012

Precision Medicine News and Research

Weill Cornell and NewYork-Presbyterian create pioneering Institute for Precision Medicine

Acute schizophrenia shows increased NMDA-R antibody prevalence

Clarient adopts QIAGEN’s therascreen KRAS test to diagnose colorectal cancer

Phenformin decreases size of lung tumors and increases survival in mice

Impulsiveness linked to severe clinical features in bipolar disorder

World Cancer Day to focus on awareness and prevention, importance of research

New apatamer can boost therapeutic effect of cell-based vaccines

SV Bio, Mayo Clinic partner on whole genome diagnostics and interpretation

Study refocuses on how neuroblastoma tumors evolve in response to medicine and other factors

Astellas announces FDA acceptance of Tarceva sNDA for EGFR activating mutation-positive NSCLC

Trovagene, MD Anderson partner to detect transrenal BRAF mutations in metastatic cancers

18F-FDG PET/CT may become important distant staging modality in patients with breast cancer

Multiple Myeloma Research Foundation, Bristol-Myers Squibb announce partnership

Pfizer joins WIN Consortium to improve personalized cancer care

New assay test shows positive results for patients with recurrent or metastatic breast cancer

New survival results from Genentech’s Perjeta Phase III combination study on HER2-positive mBC

Genomic tests increase accuracy of breast cancer diagnosis

Engineers develop simple and inexpensive way to create 3-D brain tissues in lab dishes

Study identifies gene signature associated with resistance to cancer therapies

Renowned biotech researcher to receive TJU's Lennox K. Black International Prize

Editorial Focus eBook - Peptides and Oligonucleotides (2nd edition) eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News